ICD-10 Coding for Cancer Antigen 19-9(C25.9, C25.9B, C25.9M)
Comprehensive guide on ICD-10 coding for Cancer Antigen 19-9, including primary and ancillary codes, documentation requirements, and common pitfalls.
Complete code families applicable to Cancer Antigen 19-9
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C25.9 | Malignant neoplasm of pancreas, unspecified | Use when CA 19-9 is elevated in the context of confirmed pancreatic cancer. |
|
| R97.2 | Elevated tumor marker | Use when CA 19-9 is elevated but no malignancy is confirmed. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutCancer Antigen 19-9
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Cancer Antigen 19-9.
Failing to document clinical indication for CA 19-9 testing
Impact
Clinical: May lead to inappropriate testing., Regulatory: Non-compliance with documentation standards., Financial: Potential claim denials.
Mitigation
Always include a clinical rationale in the patient's record.
Using R97.2 as a standalone code for cancer monitoring
Impact
Reimbursement: Claims may be denied due to lack of specificity., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate representation of patient condition.
Mitigation
Always pair with a primary malignancy code like C25.9.
Inadequate documentation for CA 19-9 testing
Impact
Lack of detailed clinical context can trigger audits.
Mitigation
Ensure comprehensive documentation of clinical indications and test results.